McKesson delivered strong double-digit growth in revenue, earnings, and free cash flow in fiscal 2025, outperforming the S&P 500 significantly. The planned spin-off of the underperforming Medical-Surgical Solutions segment will sharpen McKesson's focus on higher-growth, higher-margin oncology and biopharma businesses. Management and analysts expect continued double-digit earnings growth, supported by robust share buybacks and optimistic long-term guidance.
Recently, Zacks.com users have been paying close attention to McKesson (MCK). This makes it worthwhile to examine what the stock has in store.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Recently, Zacks.com users have been paying close attention to McKesson (MCK). This makes it worthwhile to examine what the stock has in store.
McKesson (MCK) concluded the recent trading session at $724.11, signifying a -1.53% move from its prior day's close.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
McKesson (MCK) closed at $705.45 in the latest trading session, marking a -3.06% move from the prior day.
McKesson (MCK) possesses solid growth attributes, which could help it handily outperform the market.
McKesson (MCK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Here is how McKesson (MCK) and Benitec Biopharma Limited (BNTC) have performed compared to their sector so far this year.